A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT00798135
First received: November 24, 2008
Last updated: September 9, 2014
Last verified: September 2014

November 24, 2008
September 9, 2014
November 2008
February 2012   (final data collection date for primary outcome measure)
Pharmacokinetics (PK) of Oral Itraconazole [ Time Frame: pre-dose at Weeks 2 and 4 ] [ Designated as safety issue: No ]
To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring mean trough plasma levels at steady state at weeks 2 and 4.
To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring trough plasma levels at steady state and to correlate measures of angiogenesis with plasma levels of itraconazole and its active metabolite hydroxyitraconazole. [ Time Frame: Baseline through week 4 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00798135 on ClinicalTrials.gov Archive Site
  • Number of Patients With Adverse Events Grade 3 or 4 That Are Related to Study Treatment [ Time Frame: up to 100 months ] [ Designated as safety issue: Yes ]
    Number of patients with Adverse Events grade 3 or 4 that are related to study treatment. This will look into the safety of the study drug.
  • Time to Progression. [ Time Frame: up to 100 months ] [ Designated as safety issue: No ]
    This is calculated as time till progression from treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. If a patient did not progress, they were censored at the last evaluation visit. The median time till progression is calculated with its 95% confidence interval.
Not Provided
Not Provided
Not Provided
 
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer

Cancer cells need to be able to make new blood vessels in order to keep growing. This is called angiogenesis. In a laboratory setting, the drug itraconazole was shown to help stop the growth of new blood vessels (anti-angiogenesis). It is hoped that itraconazole will prevent new blood vessels from forming in humans too.

The purpose of this study is to look at how the body processes and breaks down itraconazole (called pharmacokinetics). This study will also measure markers in your blood to see if itraconazole stops new blood vessels from forming. The safety of itraconazole will also be tested to see what effects (good and bad) it has on you and your breast cancer.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Breast Neoplasms
  • Neoplasm Metastasis
Drug: itraconazole
oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
Experimental: itraconazole
Patients will receive oral itraconazole 200mg a day until disease progression.
Intervention: Drug: itraconazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
13
February 2015
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

- Patients must have a pathologically confirmed diagnosis of invasive carcinoma of the breast. - Patients must carry a diagnosis of metastatic breast cancer. - Patients must be able to swallow oral medications. - Patients with HER 2+ tumors must have received trastuzumab in the past and may have had lapatinib. - Patients must have an ECOG performance status of 0-1. - Patients must be informed of the investigational nature of the study and must sign and give written informed consent. - Patients must have recovered to grade <1 from all acute toxicity of previous therapy for breast cancer with the exception of alopecia. - Adequate hematologic and hepatic function: 1)Absolute neutrophil count >= 1,500 mm3 2) Platelet count >= 100,000 mm3 3) Bilirubin <= 1.5mg/dL x ULN 4) AST and/or ALT <= 2 x ULN (< 5 x ULN in presence of known liver metastasis). - Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and must practice an effective method of birth control. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should also practice an effective method of birth control. - All WOCBP MUST have a negative serum or urine pregnancy test within 4 weeks prior to the start of study drug administration.

Exclusion Criteria:

  • Use of the following concomitant medications within 14 days of starting protocol therapy is prohibited: Cisapride, dofetilide, ergot derivatives, levomethadyl, lovastatin, midazolam, pimozide, quinidine, simvastatin, or triazolam.
  • Patients who are taking alprazolam (Xanax) are excluded from the trial.
  • Patients must not have an active infection requiring the use of intravenous antibiotics. The use of oral antibiotics is allowed.
  • Hypersensitivity to itraconazole, any component of the formulation, or to other azoles.
  • Patients with uncontrolled CNS metastasis are excluded. If patients have CNS metastasis they must have completed brain radiation at least 2 weeks prior to registration and must be off steroids for CNS metastasis.
  • Known preexisting congestive heart failure or left ventricular dysfunction. Patients with risk factors (ex. uncontrolled hypertension with BP >160/90) for cardiac dysfunction but no preexisting diagnosis of congestive heart failure or left ventricular dysfunction will have a screening EKG prior to enrollment. Subsequently, those patients with an abnormal EKG, as judged by the treating physician, will be excluded from the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00798135
0809-10; IUCRO-0239
Yes
Indiana University
Indiana University
Not Provided
Principal Investigator: Kathy Miller, MD Indiana University Melvin and Bren Simon Cancer Center
Indiana University
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP